Other OTC - Delayed Quote USD

Daiichi Sankyo Company, Limited (DSNKY)

30.86

+0.36

(+1.18%)

At close: April 25 at 3:59 PM EDT

AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.

Yahoo Finance 8 hours ago

WXIBF

WXXWY

DSKYF
-2.23%
Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Zacks 14 days ago

ARAY

4568.T
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks 17 days ago

4568.T

ADMA
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat

Benzinga 17 days ago

AZN

4568.T
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

Zacks 17 days ago

AZN

ADMA

4568.T
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors

Business Wire 20 days ago

AZN

AZNCF

DSKYF
-2.23%
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks 21 days ago

4568.T

ADMA
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Business Wire 22 days ago

DSKYF
-2.23%
DSNKY
+1.18%
MRK
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

Zacks 23 days ago

AZN

4568.T

ADMA
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & BASKING RIDGE, N.J., April 02, 2024--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease.

Business Wire 23 days ago

AZN

AZNCF

DSKYF
-2.23%
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH, March 04, 2024--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment. The other MAA is for the treatment of adult patients wi

Business Wire last month

DSKYF
-2.23%
DSNKY
+1.18%
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Zacks last month

ESPR

4568.T
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J., February 19, 2024--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Business Wire 2 months ago

AZN

AZNCF

DSKYF
-2.23%
Daiichi invests 1 bln eur near Munich to make precision cancer drugs

Daiichi Sankyo said on Friday it would invest about 1 billion euros ($1.07 billion) to expand a site near Munich, Germany, to boost its work on precision cancer drugs. The expansion project marks another welcome win to shore up the government's economic credentials after U.S. drugmaker Eli Lilly in November pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany, even as the country is likely to see a second year of recession in 2024. The investment was announced as health minister Karl Lauterbach visited the center in Pfaffenhofen, north of Daiichi's European headquarters in Munich.

Reuters 2 months ago

4568.T

LLY
Q4 2023 Merck & Co Inc Earnings Call

Q4 2023 Merck & Co Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

MRK

4568.T
AstraZeneca, Daiichi aim for first pan-tumor ADC approval

The FDA is reviewing the companies’ application for a “tumor agnostic” indication for their drug Enhertu, which would break new ground for antibody-drug conjugates.

BioPharma Dive 2 months ago

AZN

4568.T
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

TOKYO & BASKING RIDGE, N.J., January 29, 2024--ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

Business Wire 2 months ago

DSKYF
-2.23%
DSNKY
+1.18%
U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen

TOKYO & BASKING RIDGE, N.J., January 17, 2024--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.’s U.S. patent 10,808,039 (the ’039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR).

Business Wire 3 months ago

DSKYF
-2.23%
DSNKY
+1.18%
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

Investor's Business Daily 3 months ago

DSKYF
-2.23%
MRK
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Zacks 3 months ago

4568.T

CTMX

AQST

Performance Overview

Return	DSNKY	Nikkei 225
YTD	+12.83%	+13.41%
1-Year	-13.73%	+33.55%
3-Year	+7.41%	+30.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daiichi Sankyo Company, Limited (DSNKY)

AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Daiichi invests 1 bln eur near Munich to make precision cancer drugs

Q4 2023 Merck & Co Inc Earnings Call

AstraZeneca, Daiichi aim for first pan-tumor ADC approval

ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen

Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?

Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo

Performance Overview